FolusoOlabisiAdemuyiwaMD

Clinical Trials

• Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06

  Active, not recruiting

  Phase 3

• Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Start of enrollment: 2012 Dec 11

  Completed

  Phase 2

• LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer Start of enrollment: 2014 Apr 01

  Withdrawn

  Phase 2

• Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells Start of enrollment: 2013 Dec 19

  Terminated

  Phase 2

• VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors Start of enrollment: 2013 May 03

  Terminated

  Phase 1, Phase 2

• Axillary Ultrasound With or Without Sentinel Lymph Node Biopsy in Detecting the Spread of Breast Cancer in Patients Receiving Breast Conservation Therapy Start of enrollment: 2013 Apr 04

  Terminated

  Not Applicable

• Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer Start of enrollment: 2013 Jun 01

  Completed

  Phase 1

• Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity Start of enrollment: 2014 Jul 07

  Terminated

  Phase 2

• Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy Start of enrollment: 2015 Jan 07

  Active, not recruiting

  Phase 1

• Falls Risk Questionnaire in Older Adults With Cancer Start of enrollment: 2014 Aug 01

  Completed

• Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26

  Recruiting

  Phase 3

• Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer Start of enrollment: 2017 Jun 30

  Terminated

  Phase 2

• Join now to see all